Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes

A CO-MED report

Sharon C. Sung, Stephen R. Wisniewski, James F. Luther, Madhukar H. Trivedi, A. John Rush

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Most patients with major depressive disorder (MDD) report clinically significant sleep problems. Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup. This study investigated this question using data from the CO-MED trial.

Methods Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram+placebo, (2) bupropion-sustained-release+escitalopram, or (3) venlafaxine-extended-release+mirtazapine. We compared baseline characteristics, tolerability, and treatment outcomes at 12 and 28 weeks for patients with and without pre-treatment insomnia.

Results Of the 665 evaluable patients, the majority (88.3%) reported significant pre-treatment insomnia. Those with pre-treatment insomnia were more likely to be female (69.3% vs. 57.7%) and African-American (29.1% vs. 11.8%). Those with pre-treatment insomnia symptoms reported higher rates of concurrent anxiety disorders, lower rates of alcohol and substance use disorders, and greater impairment in psychosocial functioning. The two groups did not differ in either tolerability or treatment outcomes among the three antidepressant treatments.

Conclusions Insomnia symptoms, while common in patients with chronic/recurrent MDD were not predictive of response, remission, or tolerability with either single or combined antidepressant medications.

Original languageEnglish (US)
Pages (from-to)157-164
Number of pages8
JournalJournal of Affective Disorders
Volume174
DOIs
StatePublished - Mar 15 2015

Fingerprint

Sleep Initiation and Maintenance Disorders
Carbon Monoxide
Antidepressive Agents
Major Depressive Disorder
Citalopram
Therapeutics
Placebos
Bupropion
Anxiety Disorders
African Americans
Substance-Related Disorders
Sleep
Outpatients
Alcohols

Keywords

  • Antidepressant
  • Insomnia
  • Major depressive disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes : A CO-MED report. / Sung, Sharon C.; Wisniewski, Stephen R.; Luther, James F.; Trivedi, Madhukar H.; Rush, A. John.

In: Journal of Affective Disorders, Vol. 174, 15.03.2015, p. 157-164.

Research output: Contribution to journalArticle

Sung, Sharon C. ; Wisniewski, Stephen R. ; Luther, James F. ; Trivedi, Madhukar H. ; Rush, A. John. / Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes : A CO-MED report. In: Journal of Affective Disorders. 2015 ; Vol. 174. pp. 157-164.
@article{5e99e6bde8e74f5a87713ec8c5912d0e,
title = "Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report",
abstract = "Background Most patients with major depressive disorder (MDD) report clinically significant sleep problems. Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup. This study investigated this question using data from the CO-MED trial.Methods Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram+placebo, (2) bupropion-sustained-release+escitalopram, or (3) venlafaxine-extended-release+mirtazapine. We compared baseline characteristics, tolerability, and treatment outcomes at 12 and 28 weeks for patients with and without pre-treatment insomnia.Results Of the 665 evaluable patients, the majority (88.3{\%}) reported significant pre-treatment insomnia. Those with pre-treatment insomnia were more likely to be female (69.3{\%} vs. 57.7{\%}) and African-American (29.1{\%} vs. 11.8{\%}). Those with pre-treatment insomnia symptoms reported higher rates of concurrent anxiety disorders, lower rates of alcohol and substance use disorders, and greater impairment in psychosocial functioning. The two groups did not differ in either tolerability or treatment outcomes among the three antidepressant treatments.Conclusions Insomnia symptoms, while common in patients with chronic/recurrent MDD were not predictive of response, remission, or tolerability with either single or combined antidepressant medications.",
keywords = "Antidepressant, Insomnia, Major depressive disorder",
author = "Sung, {Sharon C.} and Wisniewski, {Stephen R.} and Luther, {James F.} and Trivedi, {Madhukar H.} and Rush, {A. John}",
year = "2015",
month = "3",
day = "15",
doi = "10.1016/j.jad.2014.11.026",
language = "English (US)",
volume = "174",
pages = "157--164",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes

T2 - A CO-MED report

AU - Sung, Sharon C.

AU - Wisniewski, Stephen R.

AU - Luther, James F.

AU - Trivedi, Madhukar H.

AU - Rush, A. John

PY - 2015/3/15

Y1 - 2015/3/15

N2 - Background Most patients with major depressive disorder (MDD) report clinically significant sleep problems. Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup. This study investigated this question using data from the CO-MED trial.Methods Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram+placebo, (2) bupropion-sustained-release+escitalopram, or (3) venlafaxine-extended-release+mirtazapine. We compared baseline characteristics, tolerability, and treatment outcomes at 12 and 28 weeks for patients with and without pre-treatment insomnia.Results Of the 665 evaluable patients, the majority (88.3%) reported significant pre-treatment insomnia. Those with pre-treatment insomnia were more likely to be female (69.3% vs. 57.7%) and African-American (29.1% vs. 11.8%). Those with pre-treatment insomnia symptoms reported higher rates of concurrent anxiety disorders, lower rates of alcohol and substance use disorders, and greater impairment in psychosocial functioning. The two groups did not differ in either tolerability or treatment outcomes among the three antidepressant treatments.Conclusions Insomnia symptoms, while common in patients with chronic/recurrent MDD were not predictive of response, remission, or tolerability with either single or combined antidepressant medications.

AB - Background Most patients with major depressive disorder (MDD) report clinically significant sleep problems. Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup. This study investigated this question using data from the CO-MED trial.Methods Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram+placebo, (2) bupropion-sustained-release+escitalopram, or (3) venlafaxine-extended-release+mirtazapine. We compared baseline characteristics, tolerability, and treatment outcomes at 12 and 28 weeks for patients with and without pre-treatment insomnia.Results Of the 665 evaluable patients, the majority (88.3%) reported significant pre-treatment insomnia. Those with pre-treatment insomnia were more likely to be female (69.3% vs. 57.7%) and African-American (29.1% vs. 11.8%). Those with pre-treatment insomnia symptoms reported higher rates of concurrent anxiety disorders, lower rates of alcohol and substance use disorders, and greater impairment in psychosocial functioning. The two groups did not differ in either tolerability or treatment outcomes among the three antidepressant treatments.Conclusions Insomnia symptoms, while common in patients with chronic/recurrent MDD were not predictive of response, remission, or tolerability with either single or combined antidepressant medications.

KW - Antidepressant

KW - Insomnia

KW - Major depressive disorder

UR - http://www.scopus.com/inward/record.url?scp=84918566345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918566345&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2014.11.026

DO - 10.1016/j.jad.2014.11.026

M3 - Article

VL - 174

SP - 157

EP - 164

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -